Journal ArticleDOI
4. Modelling Survival Data in Medical Research
About:
This article is published in Journal of The Royal Statistical Society Series A-statistics in Society.The article was published on 1995-01-01. It has received 1092 citations till now. The article focuses on the topics: Medical research.read more
Citations
More filters
Sequential therapy in metastatic breast cancer: survival analysis with time dependent covariates
TL;DR: Investigating the survival benefit of taxanes, after initiating chemotherapy or hormonal therapy showed that taxane was beneficial for survival in women with metastatic breast cancer, however, the effect strongly depended on the estrogen receptor type.
Journal ArticleDOI
Comparative Analysis of the Cox Semi-parametric and Weibull Parametric Models on Colorectal Cancer Data
TL;DR: This research was a five-year retrospective study on data from a record of colorectal cancer patients that received treatments from 2013 to 2017 in Radiotherapy Department of Usmanu Danfodiyo University Teaching Hospital, Sokoto, being it one of the cancer registries in Nigeria.
Dissertation
Survival, Count and Discrete Mixture Models for Analyzing Tumor Latency and Multiplicity in Carcinogenesis and Chemoprevention
TL;DR: In this article, a generalized linear model is used to estimate the survivability of a set of data points in a generalized linear model and a Poisson regression is used for the survival analysis.
Dissertation
Substance use in adolescents and young adults: Interactions of drugs of abuse and the role of parents and peers in early onset of substance use
TL;DR: In this paper, the authors explored patterns of use and important risk factors for substance use among Swedish adolescents and adults, and found that parental substance use and provision of alcohol were more influential on the adolescents' substance use than parenting styles.
Journal ArticleDOI
Bayesian accelerated failure time and its application in chemotherapy drug treatment trial
TL;DR: The Cox proportional hazards model (CPH) is normally applied in clinical trial data analysis, but it can generate severe problems with high levels of uncertainty.
References
More filters
Journal ArticleDOI
Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis
Geoffrey A. Block,Preston S. Klassen,J. Michael Lazarus,Norma J. Ofsthun,Edmund G. Lowrie,Glenn M. Chertow +5 more
TL;DR: Hyperphosphatemia and hyperparathyroidism were significantly associated with all-cause, cardiovascular, and fracture-related hospitalization, and the population attributable risk percentage for disorders of mineral metabolism was 17.5%, owing largely to the high prevalence of hyperph phosphatemia.
Journal ArticleDOI
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Roberto Pili,Georg A. Bjarnason,Xavier Garcia-del-Muro,Jeffrey A. Sosman,Ewa Solska,George Wilding,John A. Thompson,Sindy T. Kim,Isan Chen,Xin Huang,Robert A. Figlin +18 more
TL;DR: Sunitinib demonstrates longer overall survival compared with IFN-alpha plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC, highlighting an improved prognosis in patients with RCC in the era of targeted therapy.
Journal ArticleDOI
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote,Claes G. Tropé,Frédéric Amant,G.B. Kristensen,Tom Ehlen,N Johnson,René H.M. Verheijen,Maria E. L. van der Burg,A. J. Lacave,Pierluigi Benedetti Panici,Gemma G. Kenter,Antonio Casado,Cesar Mendiola,Corneel Coens,Leen Verleye,Gavin Stuart,Sergio Pecorelli,Nicholas Reed +17 more
TL;DR: Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulked surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study.
Journal ArticleDOI
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
TL;DR: Five prognostic factors for predicting survival were identified and used to categorize patients with metastatic RCC into three risk groups, for which the median survival times were separated by 6 months or more.